SINGAPORE (July 3): Only 1% of the hundreds of leads that is being reviewed yearly by The Trendlines Group is selected to be its portfolio company.

The leads not only come from Israel, but also Singapore, Malaysia, Australia and Thailand.

Over the past 12 months, Trendlines’ management has implemented several measures that demonstrated its commitment to shareholders.

This included its plans last Oct to reduce FY18 operating expenses by US$1.3 million ($1.8 million). In April,  CEOs of the groups also won approval from shareholders to peg their 2018 bonuses to defined targets and stipulated limits.

Soon Trendlines will launch of B. Braun’s new ostomy product licensed from its portfolio company Stimatix GI which is also the group’s Most Valuable Portfolio Company. Royalties from the sale of the product will supplement operating cash flows.

Other portfolio companies have also gained good momentum this year. BioFishency recorded sales of US$0.8 million in 1Q18 following sales of only US$0.55 million in 2017. Likewise, EdenShield is targeting sales of US$2.5 million for 2018, following sales of US$0.45 million in 2017.

As at 11.50am, Trendlines is trading at 12 cents, or about 0.6 times its book value as at March 31. Market capitalisation of $72.4 million is backed by cash net current assets of $16.6 million and a portfolio value of US$97.4 million or an average of US$1.16 million per portfolio company -- excluding Stimatix GI -- as at March 31.

In a recent report, NRA Capital is maintaining Trendlines at “overweight” with a fair value of 22.5 cents.

“We reiterate that Trendlines remains undervalued ... with a high-average return and average risk view,” says analyst Liu Jinshu.

This start-up discoverer remains undervalued

Frasers Property sells 286 units in 9MFY2022, readies former Bedok Point for launch 

LMIRT's DPU stabilisies in 2Q but NAV declines as gearing inches higher

APAC Realty clocks 1HFY2022 earnings of $16.6 million, plans 3.5 cents interim dividend

Plugging the cybersecurity talent gap in Singapore

Racing towards the future of healthcare 

Driving into a smart mobility future

The US-led drive to isolate Russia and China is falling short

This start-up discoverer remains undervalued

Related Stories

Highlights

Keppel Infrastructure Trust and other Keppel units to acquire South Korean waste management firm for $666 mil

Related Stories

Trendlines to report a loss for 1HFY2022 with US$7.9 mil portfolio company write-off

Phytolon closes US$14.5 million in Series A Funding

Trendlines to raise $20.27 million through proposed subscription of 168.9 mil new shares